Telix Pharmaceuticals Logo
Telix Pharmaceuticals Logo
  • Our Company
    • Our Company
    • Purpose, Mission & Values
    • Board & Management
    • Our Technology
    • Sustainability
  • Our Portfolio
    • Our Portfolio
    • Disease Areas
      • Prostate Cancer
      • Kidney Cancer
      • Brain Cancer
      • Musculo-skeletal cancers
    • Clinical Trials
    • Illuccix® & Gozellix®
    • Pipeline
    • Research & Innovation
  • Investor Centre
  • News & Views
  • Careers
    • Careers
    • Find a job
Header Image Frame Header Image Frame

Home Clinical Page 12

News & Views

Latest News

Category: Clinical

See all

Telix Receives FDA Feedback on Phase 3 Trial Design for Prostate Cancer Therapy Product

Clinical, News,

Telix Pharmaceuticals Limited announces that the FDA has provided feedback that will enable the Company to finalize the Phase 3 PROSTACT...

Read more

Recommencement of ZIRCON Phase III Trial Recruitment in EU

Clinical, News,

Telix Pharmaceuticals Limited announces that the Company’s ZIRCON phase III trial of TLX250-CDx has recommenced patient recruitment in...

Read more

Telix Granted FDA Approval for ZIRCON Renal Cancer Imaging

Clinical, News,

Telix Pharmaceuticals Limited is pleased to announce that the FDA has approved the ZIRCON study for American...

Read more

NDA Clinical Briefing Package Submitted to the US FDA

Clinical, News,

Telix Pharmaceuticals announces that it has submitted a complete clinical briefing package to the US FDA for its first product...

Read more

ZIRCON Phase 3 IND Submitted to the US FDA

Clinical, News,

Telix Pharmaceuticals Limited announces that it has submitted a Phase 3 IND application to the FDA for...

Read more

TLX101 for Brain Cancer IPAX-1 Study Update

Clinical, News,

Telix Pharmaceuticals has released an update on the progress of its TLX101 product in the treatment of glioblastoma...

Read more

Telix Pharmaceuticals Program Update Q3 2019

Clinical, News,

Telix Pharmaceuticals Limited is pleased to release a Clinical Trial Program Update for Q3,...

Read more

Telix Cleared to Commence Renal Cancer Imaging Study in Japan

Clinical, News,

Telix Pharmaceuticals Limited is pleased to announce the completion of a Clinical Trial Notification (CTN) review for a Phase I/II study for TLX250-CDx (89Zr-girentuximab) in...

Read more

First Australian Patient Dosed in ZIRCON Phase III Trial

Clinical, News,

Telix Pharmaceuticals Limited is pleased to announce that the first Australian patient has been added to the Phase III ZIRCON study.  The first Australian patient was dosed with TLX250-CDx at...

Read more

Telix Pharmaceuticals launches information site on illumet™ prostate cancer imaging product

Clinical, News,

Telix has just launched an information site on our illumet™ prostate cancer imaging product. The website provides an informative depository about how the product works and its potential in clinical...

Read more

Posts pagination

1 … 11 12 13

Subscribe

* indicates required

By subscribing, you are agreeing to the terms of our Global Privacy Policy and provide consent to receive updates from Telix”

Telix Pharmaceuticals Logo
  • Our Company
  • Contact
  • Our Portfolio
  • Careers
  • Investor Centre
  • News & Views
  • Telix Hotline
  • Consumer Health Privacy Notice

© Telix Pharmaceuticals Limited. 55 Flemington Road, North Melbourne, VIC 3051, Australia.

The Telix Pharmaceuticals and the Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved.
This website is intended for corporate communication purposes only and is not intended as promotion or advertising to any audience in any country worldwide.

Privacy Policy. Terms of Use. Cookies Policy. Privacy Settings